Home
Issues
Deals
Ledger
Research
About
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 16 · Tue 29 Sep
All issues
Compass Pathways
Every issue covering Compass Pathways.
9 issues
2026-09-22
No. 15
The CVR is an option, and Lilly holds it
DEALS
REGULATORY
TRIALS
LILLY
ATAIBECKLEY
COMPASS
ABBVIE
OTSUKA
2026-09-15
No. 14
Five countries, one regulator.
TRIALS
DEALS
REGULATORY
DEFINIUM
LILLY
ATAIBECKLEY
COMPASS
GH
2026-08-04
No. 9
No European application on file for the world's most advanced psilocybin programme
REGULATORY
ACCESS
COMPASS
2026-07-14
No. 6
Compass just put a date on the first Western psychedelic launch: the first half of 2027.
TRIALS
ACCESS
COMPASS
CYBIN
2026-07-07
No. 5
European psychedelic depression development just split into two camps.
TRIALS
COMPASS
BECKLEY-PSYTECH
CYBIN
2026-06-30
No. 4
LSD just posted the biggest depression number in psychedelic Phase 3 history.
TRIALS
RESEARCH
DEFINIUM
COMPASS
2026-06-23
No. 3
Europe's most advanced psychedelic Phase 3 is staked on the one indication that got harder last week.
TRIALS
RESEARCH
COMPASS
CYBIN
2026-06-11
European Psychedelic Medicine: H1 2026 in Review
RESEARCH
DEALS
COMPASS
ATAIBECKLEY
BECKLEY-PSYTECH
GH
2026-06-09
No. 1
Psychedelic Brief
RESEARCH
ACCESS
GH
COMPASS